Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25


Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells.

Mastelic-Gavillet B, Navarro Rodrigo B, Décombaz L, Wang H, Ercolano G, Ahmed R, Lozano LE, Ianaro A, Derré L, Valerio M, Tawadros T, Jichlinski P, Nguyen-Ngoc T, Speiser DE, Verdeil G, Gestermann N, Dormond O, Kandalaft L, Coukos G, Jandus C, Ménétrier-Caux C, Caux C, Ho PC, Romero P, Harari A, Vigano S.

J Immunother Cancer. 2019 Oct 10;7(1):257. doi: 10.1186/s40425-019-0719-5.


Maf deficiency in T cells dysregulates Treg - TH17 balance leading to spontaneous colitis.

Imbratta C, Leblond MM, Bouzourène H, Speiser DE, Velin D, Verdeil G.

Sci Rep. 2019 Apr 16;9(1):6135. doi: 10.1038/s41598-019-42486-2.


More T Cells versus Better T Cells in Patients with Breast Cancer.

Speiser DE, Verdeil G.

Cancer Discov. 2017 Oct;7(10):1062-1064. doi: 10.1158/2159-8290.CD-17-0858.


Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.

Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salomé B, Lecciso M, Salvestrini V, Verdeil G, Racle J, Papayannidis C, Morita H, Pizzitola I, Grandclément C, Bohner P, Bruni E, Girotra M, Pallavi R, Falvo P, Leibundgut EO, Baerlocher GM, Carlo-Stella C, Taurino D, Santoro A, Spinelli O, Rambaldi A, Giarin E, Basso G, Tresoldi C, Ciceri F, Gfeller D, Akdis CA, Mazzarella L, Minucci S, Pelicci PG, Marcenaro E, McKenzie ANJ, Vanhecke D, Coukos G, Mavilio D, Curti A, Derré L, Jandus C.

Nat Commun. 2017 Sep 19;8(1):593. doi: 10.1038/s41467-017-00678-2.


Peripheral Deletion of CD8 T Cells Requires p38 MAPK in Cross-Presenting Dendritic Cells.

Smith T, Lin X, Mello M, Marquardt K, Cheung J, Lu B, Sherman LA, Verdeil G.

J Immunol. 2017 Oct 15;199(8):2713-2720. doi: 10.4049/jimmunol.1700427. Epub 2017 Sep 1.


Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients.

Murray T, Fuertes Marraco SA, Baumgaertner P, Bordry N, Cagnon L, Donda A, Romero P, Verdeil G, Speiser DE.

Front Immunol. 2016 Dec 12;7:573. doi: 10.3389/fimmu.2016.00573. eCollection 2016.


Distinct patterns of cytolytic T-cell activation by different tumour cells revealed by Ca2+ signalling and granule mobilization.

Frick M, Mouchacca P, Verdeil G, Hamon Y, Billaudeau C, Buferne M, Fallet M, Auphan-Anezin N, Schmitt-Verhulst AM, Boyer C.

Immunology. 2017 Feb;150(2):199-212. doi: 10.1111/imm.12679. Epub 2016 Nov 2.


Regulatory circuits of T cell function in cancer.

Speiser DE, Ho PC, Verdeil G.

Nat Rev Immunol. 2016 Oct;16(10):599-611. doi: 10.1038/nri.2016.80. Epub 2016 Aug 16. Review.


MAF drives CD8+ T-cell exhaustion.

Verdeil G.

Oncoimmunology. 2015 Aug 31;5(2):e1082707. eCollection 2016 Feb.


Inhibitory Receptors Beyond T Cell Exhaustion.

Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE.

Front Immunol. 2015 Jun 26;6:310. doi: 10.3389/fimmu.2015.00310. eCollection 2015. Review.


Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion.

Giordano M, Henin C, Maurizio J, Imbratta C, Bourdely P, Buferne M, Baitsch L, Vanhille L, Sieweke MH, Speiser DE, Auphan-Anezin N, Schmitt-Verhulst AM, Verdeil G.

EMBO J. 2015 Aug 4;34(15):2042-58. doi: 10.15252/embj.201490786. Epub 2015 Jul 2.


From T cell "exhaustion" to anti-cancer immunity.

Verdeil G, Fuertes Marraco SA, Murray T, Speiser DE.

Biochim Biophys Acta. 2016 Jan;1865(1):49-57. doi: 10.1016/j.bbcan.2015.06.007. Epub 2015 Jun 27. Review.


Unleashing antitumor T-cell activation without ensuing autoimmunity: the case for A20-deletion in adoptive CD8+ T-cell therapy.

Verdeil G, Schmitt-Verhulst AM.

Oncoimmunology. 2014 Dec 15;3(10):e958951. eCollection 2014 Oct.


Contribution of TCR signaling strength to CD8+ T cell peripheral tolerance mechanisms.

Smith TR, Verdeil G, Marquardt K, Sherman LA.

J Immunol. 2014 Oct 1;193(7):3409-16. doi: 10.4049/jimmunol.1401194. Epub 2014 Aug 25.


The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells.

Giordano M, Roncagalli R, Bourdely P, Chasson L, Buferne M, Yamasaki S, Beyaert R, van Loo G, Auphan-Anezin N, Schmitt-Verhulst AM, Verdeil G.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11115-20. doi: 10.1073/pnas.1406259111. Epub 2014 Jul 14.


Active STAT5 regulates T-bet and eomesodermin expression in CD8 T cells and imprints a T-bet-dependent Tc1 program with repressed IL-6/TGF-β1 signaling.

Grange M, Verdeil G, Arnoux F, Griffon A, Spicuglia S, Maurizio J, Buferne M, Schmitt-Verhulst AM, Auphan-Anezin N.

J Immunol. 2013 Oct 1;191(7):3712-24. doi: 10.4049/jimmunol.1300319. Epub 2013 Sep 4.


Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells?

Auphan-Anezin N, Verdeil G, Grange M, Soudja SM, Wehbe M, Buferne M, Mas A, Schmitt-Verhulst AM.

Pigment Cell Melanoma Res. 2013 Mar;26(2):167-75. doi: 10.1111/pcmr.12056. Epub 2012 Dec 27.


Epithelial-mesenchymal-transition-like and TGFβ pathways associated with autochthonous inflammatory melanoma development in mice.

Wehbe M, Soudja SM, Mas A, Chasson L, Guinamard R, de Tenbossche CP, Verdeil G, Van den Eynde B, Schmitt-Verhulst AM.

PLoS One. 2012;7(11):e49419. doi: 10.1371/journal.pone.0049419. Epub 2012 Nov 16.


Activated STAT5 promotes long-lived cytotoxic CD8+ T cells that induce regression of autochthonous melanoma.

Grange M, Buferne M, Verdeil G, Leserman L, Schmitt-Verhulst AM, Auphan-Anezin N.

Cancer Res. 2012 Jan 1;72(1):76-87. doi: 10.1158/0008-5472.CAN-11-2187. Epub 2011 Nov 7.


Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy.

Verdeil G, Marquardt K, Surh CD, Sherman LA.

Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16683-8. doi: 10.1073/pnas.0805054105. Epub 2008 Oct 20.


CD8 T cell help for innate antitumor immunity.

Shanker A, Verdeil G, Buferne M, Inderberg-Suso EM, Puthier D, Joly F, Nguyen C, Leserman L, Auphan-Anezin N, Schmitt-Verhulst AM.

J Immunol. 2007 Nov 15;179(10):6651-62.


Temporal cross-talk between TCR and STAT signals for CD8 T cell effector differentiation.

Verdeil G, Chaix J, Schmitt-Verhulst AM, Auphan-Anezin N.

Eur J Immunol. 2006 Dec;36(12):3090-100. Review.


STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors.

Verdeil G, Puthier D, Nguyen C, Schmitt-Verhulst AM, Auphan-Anezin N.

J Immunol. 2006 Apr 15;176(8):4834-42.


Gene profiling approach to establish the molecular bases for partial versus full activation of naïve CD8 T lymphocytes.

Verdeil G, Puthier D, Nguyen C, Schmitt-Verhulst AM, Auphan-Anezin N.

Ann N Y Acad Sci. 2002 Dec;975:68-76.


Supplemental Content

Loading ...
Support Center